These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14663013)

  • 1. Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists.
    Castagnoli N; Petzer JP; Steyn S; Castagnoli K; Chen JF; Schwarzschild MA; Van der Schyf CJ
    Neurology; 2003 Dec; 61(11 Suppl 6):S62-8. PubMed ID: 14663013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists.
    Petzer JP; Steyn S; Castagnoli KP; Chen JF; Schwarzschild MA; Van der Schyf CJ; Castagnoli N
    Bioorg Med Chem; 2003 Apr; 11(7):1299-310. PubMed ID: 12628657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke.
    Khalil AA; Davies B; Castagnoli N
    Bioorg Med Chem; 2006 May; 14(10):3392-8. PubMed ID: 16458520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors.
    Brunschweiger A; Koch P; Schlenk M; Rafehi M; Radjainia H; Küppers P; Hinz S; Pineda F; Wiese M; Hockemeyer J; Heer J; Denonne F; Müller CE
    Bioorg Med Chem; 2016 Nov; 24(21):5462-5480. PubMed ID: 27658798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO).
    Herraiz T; Arán VJ; Guillén H
    Free Radic Res; 2009 Oct; 43(10):975-84. PubMed ID: 19669997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective aspects of a novel MAO-B inhibitor PF9601N.
    Pérez V; Morón J; Pastó M; Unzeta M
    Neurobiology (Bp); 2000; 8(3-4):231-6. PubMed ID: 11225513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
    Koch P; Akkari R; Brunschweiger A; Borrmann T; Schlenk M; Küppers P; Köse M; Radjainia H; Hockemeyer J; Drabczyńska A; Kieć-Kononowicz K; Müller CE
    Bioorg Med Chem; 2013 Dec; 21(23):7435-52. PubMed ID: 24139167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
    Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
    Bioorg Chem; 2015 Apr; 59():117-23. PubMed ID: 25746740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
    Yeon SK; Choi JW; Park JH; Lee YR; Kim HJ; Shin SJ; Jang BK; Kim S; Bahn YS; Han G; Lee YS; Pae AN; Park KD
    Bioorg Med Chem; 2018 Jan; 26(1):232-244. PubMed ID: 29198609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC).
    Vlok N; Malan SF; Castagnoli N; Bergh JJ; Petzer JP
    Bioorg Med Chem; 2006 May; 14(10):3512-21. PubMed ID: 16442801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
    Tao D; Wang Y; Bao XQ; Yang BB; Gao F; Wang L; Zhang D; Li L
    Eur J Med Chem; 2019 Jul; 173():203-212. PubMed ID: 31005056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs.
    Youngster SK; Sonsalla PK; Sieber BA; Heikkila RE
    J Pharmacol Exp Ther; 1989 Jun; 249(3):820-8. PubMed ID: 2786564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies.
    Załuski M; Schabikowski J; Schlenk M; Olejarz-Maciej A; Kubas B; Karcz T; Kuder K; Latacz G; Zygmunt M; Synak D; Hinz S; Müller CE; Kieć-Kononowicz K
    Bioorg Med Chem; 2019 Apr; 27(7):1195-1210. PubMed ID: 30808606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain.
    Fuller RW; Robertson DW; Hemrick-Luecke SK
    J Pharmacol Exp Ther; 1987 Feb; 240(2):415-20. PubMed ID: 3100775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism.
    Chen JF; Steyn S; Staal R; Petzer JP; Xu K; Van Der Schyf CJ; Castagnoli K; Sonsalla PK; Castagnoli N; Schwarzschild MA
    J Biol Chem; 2002 Sep; 277(39):36040-4. PubMed ID: 12130655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel, Dual Target-Directed Annelated Xanthine Derivatives Acting on Adenosine Receptors and Monoamine Oxidase B.
    Kuder KJ; Załuski M; Schabikowski J; Latacz G; Olejarz-Maciej A; Jaśko P; Doroz-Płonka A; Brockmann A; Müller CE; Kieć-Kononowicz K
    ChemMedChem; 2020 May; 15(9):772-786. PubMed ID: 32162782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease.
    Petzer JP; Petzer A
    Curr Med Chem; 2015; 22(8):975-88. PubMed ID: 25544641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.